Successful First Trial for Dizziness Monitoring Device

A ground-breaking device to help patients with dizziness problems has moved a step forward following a successful research study. Researchers from UEA and the Norfolk and Norwich University Hospital (NNUH) have published the results of the biggest collection of continuous eye movement data after testing the effectiveness of a wearable diagnostic headset.

The Continuous Ambulatory Vestibular Assessment (CAVA) aims to speed up the diagnosis of the most common causes of dizziness.

A study into the accuracy, reliability and safety of the novel new device, published in the journal Scientific Reports, found the technology to be 99 per cent accurate at detecting eye flicker (nystagmus).

In the trial, the CAVA device was worn by 17 participants, who did not have dizziness problems, for up to 30 days and captured 9,000 hours of eye and head movement data, totalling 405 days of data.

The CAVA device has been designed to be lightweight, durable and can be worn day and night to monitor head and eye movements to help evaluate dizziness attacks outside of a hospital setting.

Prof Stephen Cox and Dr Jacob Newman, from UEA's School of Computing Sciences, developed algorithms to identify seconds of nystagmus from weeks of data recorded by the device.

Principal Investigator John Phillips, who is a Consultant Ear, Nose and Throat Surgeon at NNUH, said the first phase of trialling the device had involved inducing eye flicker on healthy patients.

"Following years of development, I'm delighted that this project was successful in identifying short periods of visually induced nystagmus with a high degree of accuracy," he said.

"The success of this trial has proven the potential of this to fulfil a clinical need and establishing a new field of medicine, vestibular telemetry. These results have provided a good foundation from which to conduct a further study intended to evaluate the system's diagnostic accuracy among patients with dizziness problems."

Dr Jacob Newman, from UEA's School of Computing Sciences, said: "We are very pleased that our algorithms have been able to detect such small incidences of nystagmus within such a large dataset, this bodes well for future work that considers nystagmus in individuals experiencing dizziness."

The study was funded by the Medical Research Council.

John S. Phillips, Jacob L Newman, Stephen J Cox.
An investigation into the diagnostic accuracy, reliability, acceptability and safety of a novel device for Continuous Ambulatory Vestibular Assessment (CAVA).
Scientific Reportsvolume 9, Article number: 10452 (2019). doi: 10.1038/s41598-019-46970-7.

Most Popular Now

ChatGPT 4o Therapeutic Chatbot 'Ama…

One of the first randomized controlled trials assessing the effectiveness of a large language model (LLM) chatbot 'Amanda' for relationship support shows that a single session of chatbot therapy...

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...

AI Body Composition Measurements can Pre…

Adiposity - or the accumulation of excess fat in the body - is a known driver of cardiometabolic diseases such as heart disease, stroke, type 2 diabetes, and kidney disease...